The prevention and treatment of venous thromboembolism with LMWHs and new anticoagulants

References

• WhiteRHThe epidemiology of venous thromboembolismCirculation200310723 Suppl 11418
   Google Scholar
• HeitJAVenous thromboembolism: disease burden, outcomes and risk factorsJ Thromb Haemost200531611161716102026
   PubMed Web of Science ®Google Scholar
• AndersonFASpencer FA. Risk factors for venous thromboembolismCirculation2003107I9I1612814980
   PubMed Web of Science ®Google Scholar
• BlannADLipGYHVenous thromboembolismBr Med J200633221521916439400
   PubMedGoogle Scholar
• HeparinJHirsh HeparinN Engl J Med1991324156515742027360
   PubMedGoogle Scholar
• BullerHRSohneMMiddeldorpSTreatment of venous thromboembolismJ Thromb Haemost200531554156016102019
   PubMed Web of Science ®Google Scholar
• TurpieAGChinBSLipGYVenous thromboembolism: pathophysiology, clinical features and preventionBr Med J200232588789012386044
   PubMed Web of Science ®Google Scholar
• Schmidt-MulheimABeitrage zur Kenntnis des peptones under seiner physiologischen BedeutungArchiv fur Anatomie und Physiologie Physiologische Abteilung18803356
   Google Scholar
• DoyonMRapports du foie avec la coagulation du sangJournal de Physiologie et de Pathologie General191214229240
   Google Scholar
• McLeanJThe thromboplastinics action of cephalinAm J Physiol191641250257
   Google Scholar
• HowellWHHeparin and anticoagulationAm J Physiol192363434435
   Google Scholar
• JorpesJEThe chemistry of heparinBiochem J1935291817183016745848
   PubMedGoogle Scholar
• CrafoordCPreliminary report on post-operative treatment with heparin as a preventative of thrombosisActa Chir Scand193779407426
   Google Scholar
• BestCHPreparation of heparin and its use in the first clinical caseCirculation195919798613619024
   PubMed Web of Science ®Google Scholar
• BrinkhousKMSmithHPWarnerEDSeegersWHThe inhibition of blood clotting: an unidentified substance which acts in conjunction with heparin to prevent the conversion of prothrombin to thrombinAm J Physiol1939125683687
   Google Scholar
• BeelerDRosenbergRJordanRFractionation of low molecular weight heparin species and the interaction with antithrombinJ Biol Chem197925429022913429327
   PubMed Web of Science ®Google Scholar
• BarrowcliffeTWJohnsonEAEggletonCAKemball-CookGThorneDPAnticoagulant activities of high and low molecular weight heparin fractionsBr J Haematol197941573583435404
   PubMed Web of Science ®Google Scholar
• KakkarVVDjazaeriBFokMScullyMFWestwickJLow molecular weight heparin and prevention of postoperative deep vein thrombosisBr Med J19822843753796800465
   PubMed Web of Science ®Google Scholar
• HirshJOfosuFBuchananMRationale behind the development of low molecular weight heparin derivativesSemin Thromb Haemost1985111316
   PubMed Web of Science ®Google Scholar
• RoemischJGrayEHoffmannJNWiedermannCJAntithrombin: a new look at the actions of a serine protease inhibitorBlood Coag Fibrinolysis200213657670
   PubMed Web of Science ®Google Scholar
• SalzmanEWRosenbergRDSmithMHLindonJNFavreauLEffects of heparin and heparin fractions on platelet aggregationJ Clin Invest19806564736243142
   PubMed Web of Science ®Google Scholar
• BlajchmanMAYoungEOfusuFAEffects of unfractionated heparin, dermatan sulphate and low molecular weight heparin on vessel wall permeability in rabbitsAnn NY Acad Sci19895562452542544126
   PubMed Web of Science ®Google Scholar
• LindahlUHookMGlycosaminoglycans and their binding to biological macromoleculesAnn Rev Biochem197847385417354500
   PubMed Web of Science ®Google Scholar
• CipolleRSeifertRNeilanBZaskeDEHasusEHeparin kinetics: variables related to disposition and dosageClin Pharmacol Ther1981293873937471609
   PubMed Web of Science ®Google Scholar
• ShojaniaAMTetreaultJTurnbullJLThe variations between heparin sensitivity of different lots of activated partial thromboplastin time reagent produced by the same manufacturerAm J Clin Pathol19888919233337049
   PubMed Web of Science ®Google Scholar
• HyersTMAgnelliGHullRDAntithrombotic therapy for venous thromboembolic diseaseChest2001119176S193S11157648
   PubMed Web of Science ®Google Scholar
• TurpieAGGChinBSPLipGYHVenous thromboembolism: treatment strategiesBr Med J200232594895012399348
   PubMed Web of Science ®Google Scholar
• BarrittDWJordanSCAnticoagulant drugs in the treatment of pulmonary embolus: a controlled clinical trialLancet1960171381309131213797091
   PubMed Web of Science ®Google Scholar
• KernohanRJToddCHeparin therapy in thromboembolic diseaseLancet1966174386216234159671
   PubMed Web of Science ®Google Scholar
• SalzmanEWDeykinDShaprioMRRosenbergRManagement of heparin therapy: controlled prospective trialN Engl J Med1975292104610501091856
   PubMed Web of Science ®Google Scholar
• HullRDRaskobGEHirshJContinuous intravenous heparin compared with intermittent subcutaneous heparin in the initial treatment of proximal-vein thrombosisN Engl J Med1986315110911143531862
   PubMed Web of Science ®Google Scholar
• BrandjesDPMHeijboerHBullerHRde RijkMJagtHten CateJWAcenocoumarol and heparin compared with acenocoumarol alone in the initial treatment of proximal vein thrombosisN Engl J Med1992327148514891406880
   PubMed Web of Science ®Google Scholar
• SchulmanSRhedinASLindmarkerPA comparison of six weeks of oral anticoagulant therapy after a first episode of venous thromboembolism. Duration of anticoagulation trial study groupN Engl J Med1995332166116657760866
   PubMed Web of Science ®Google Scholar
• TurpieAGHirschJProphylaxis and therapy of venous thromboembolismCRC Crit Rev Clin Lab Sci197910247274380902
   PubMed Web of Science ®Google Scholar
• GallusAJackamanJTillettJMillsWWycherleyASafety and efficacy of warfarin started early after submassive proximal venous thrombosis or pulmonary embolusLancet198628519129312962878173
   PubMed Web of Science ®Google Scholar
• WeismannRETobinRWArterial embolism occurring during systemic heparin therapyArch Surg195876219227
   Web of Science ®Google Scholar
• ChongBHHeparin induced thrombocytopeniaJ Thromb Haemost200311471147812871282
   PubMed Web of Science ®Google Scholar
• WarkentinTEHeparin induced thrombocytopenia. A ten year retrospectiveAnnu Rev Med19995012914710073268
   PubMed Web of Science ®Google Scholar
• WarkentinTECurrent agents for the treatment of patients with heparin induced thrombocytopeniaCurr Opin Pulm Med2002840541212172444
   PubMed Web of Science ®Google Scholar
• XiaoZTherouxPPlatelet activation with unfractionated heparin at therapeutic concentrations and comparisons with a low molecular weight heparin and with a direct thrombin inhibitorCirculation1998972512569462526
   PubMed Web of Science ®Google Scholar
• YusufSMehtaSRChrolaviciusSComparison of fondaparinux and enoxaparin in acute coronary syndromesN Engl J Med20063541464147616537663
   PubMed Web of Science ®Google Scholar
• WarkentinTELevineMNHirshJHeparin-induced thrombocytopenia in patients treated with low molecular weight heparin or unfractionated heparinN Engl J Med1995332133013357715641
   PubMed Web of Science ®Google Scholar
• SquiresJWPinchLWHeparin induced spinal fracturesJAMA197924124172418439319
   PubMed Web of Science ®Google Scholar
• SacklerJPLiuLHeparin induced osteoporosisBr J Radiol197346458460
   Web of Science ®Google Scholar
• GinsbergJSKowalchukGHirschJHeparin effect on bone densityThromb Haemost1990642862892270535
   PubMed Web of Science ®Google Scholar
• EdesTESunderrajanEVHeparin-induced hyperkalaemiaArch Intern Med1985145107010724004433
   PubMedGoogle Scholar
• DukesGEJrSandersSWRussoJJrTransaminase elevations in patients receiving bovine or porcine heparinAnn Intern Med19841006466506712030
   PubMed Web of Science ®Google Scholar
• HirschJDalenJEDeykinDPollerLHeparin: Mechanism of action, pharmacokinetics, dosing considerations, monitoring, efficacy, safetyChest1992102Suppl337S351S1327666
   PubMedGoogle Scholar
• TurpieAGGCan we differentiate the low molecular weight heparins?Clin Cardiol200023Suppl II4I710680037
   PubMedGoogle Scholar
• OffordRPerryDAnticoagulationLondon, UKScience Press2002
   Google Scholar
• HirshJWarkentinTEShaughnessySGHeparin and low molecular weight heparin. Mechanism of action, pharmacokinetics, dosing, monitoring, efficacy, safetyChest2001119Suppl64S94S11157643
   PubMedGoogle Scholar
• LensingAWAPrinsMHDavidsonBLHirshJTreatment of deep vein thrombosis with low molecular weight heparins. A meta-analysisArch Intern Med19951556016077887755
   PubMed Web of Science ®Google Scholar
• LeizoroviczASimonneauGDecoususHBoisselJPComparison of efficacy and safety of low molecular weight heparins and unfractionated heparin in initial treatment of deep vein thrombosis: a meta analysisBr Med J19943096486518086990
   PubMedGoogle Scholar
• SiragusaSCosmiBPiovellaFHirschJGinsbergGLow molecular weight heparins an unfractionated in the treatment of patients with acute venous thromboembolism. Results of a meta-analysisAm J Med19961002692778629671
   PubMed Web of Science ®Google Scholar
• Low-molecular-weight heparin in the treatment of patients with venous thromboembolism. The Columbus InvestigatorsN Engl J Med19973376576629280815
   PubMed Web of Science ®Google Scholar
• SimonneauGSorsHCharbonnierBfor the THESEE study groupA comparison of low molecular weight heparin with unfractionated heparin for acute pulmonary embolismN Engl J Med19973376636699278462
   PubMed Web of Science ®Google Scholar
• GouldMKDembitzerADDoyleRLLow molecular weight heparins compared with unfractionated heparin for the treatment of acute deep vein thrombosis: a meta-analysis of randomised controlled trialsAnn Intern Med199913080080910366369
   PubMed Web of Science ®Google Scholar
• NorrbyKHeparin and angiogenesis: a low-molecular-weight fraction inhibits and a high-molecular-weight fraction stimulates angiogenesis systemicallyHaemostasis199323Suppl 11411497684350
   PubMedGoogle Scholar
• SjälanderAJanssonJHBergqvistDErikssonHCarlbergBSvenssonPEfficacy and safety of anticoagulant prophylaxis to prevent venous thromboembolism in acutely ill medical inpatients: a meta-analysisJ Intern Med2008263526018088252
   PubMed Web of Science ®Google Scholar
• LevineMGentMHirschJA comparison of low molecular weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep vein thrombosisN Engl J Med19963346776818594425
   PubMed Web of Science ®Google Scholar
• KoopmanMMWPrandoniPPiovellaFTreatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous LMWH administered at homeN Engl J Med19963346826878594426
   PubMed Web of Science ®Google Scholar
• OmranHHammerstinglCSchmidtHvon der ReckeGPaarWDLüderitzBA prospective and randomised comparison off the safety and effects of therapeutic levels of enoxaparin versus unfractionated heparin in chronically anticoagulated patients undergoing elective cardiac catheterisationThromb Haemost20039026727112888874
   PubMed Web of Science ®Google Scholar
• JacksonMRClagettGPAntithrombotic therapy in peripheral arterial occlusive diseaseChest2001119283S299S11157655
   PubMed Web of Science ®Google Scholar
• LeeAYThe role of low molecular weight heparins in the prevention and treatment of venous thromboembolism in cancer patientsCurr Opin Pulm Med2003935135512904702
   PubMed Web of Science ®Google Scholar
• LeeAYLevineMNBakerRILow-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancerN Engl J Med200334914615312853587
   PubMed Web of Science ®Google Scholar
• KhoranaAAThe NCCN Clinical Practice Guidelines on Venous Thromboembolic Disease: strategies for improving VTE prophylaxis in hospitalized cancer patientsOncologist2007121361137018055857
   PubMed Web of Science ®Google Scholar
• LevineMNLeeAYKakkarAKFrom Trousseau to targeted therapy: New insights and innovations in thrombosis and cancerJ Thromb Haemost200311456146312871280
   PubMed Web of Science ®Google Scholar
• FolsomARCushmanMTsaiMYA prospective study of venous thromboembolism in relation to factor V Leiden and related factorsBlood2002992720272511929758
   PubMed Web of Science ®Google Scholar
• SchulmanSUnresolved issues in anticoagulant therapyJ Thromb Haemost200311464147012871281
   PubMed Web of Science ®Google Scholar
• KnightCJPanseartMWilsonDJIncreased platelet responsiveness following coronary stentingEur Heart J199819123912489740346
   PubMed Web of Science ®Google Scholar
• The British National FormularyIssue 57. 2009. Available from http://www.bnf.org/ Accessed March 10, 2009.
   Google Scholar
• TurpieAGBauerKAErikssonBILassenMRFondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: a meta-analysis of 4 randomized double-blind studiesArch Intern Med20021621833184012196081
   PubMed Web of Science ®Google Scholar
• HirshJGuyattGAlbersGWAntithrombotic and thrombolytic therapy. American College of Chest Physicians. Evidence-Based Clinical Practice Guidelines (8th Edition)Chest20081336 Suppl71S109S Errata in: Chest. 2008;134:473 and Chest. 2008;134:892.18574259
   PubMed Web of Science ®Google Scholar
• British Thoracic Society Standards of Care Committee Pulmonary Embolism Guideline Development GroupBritish Thoracic Society Standards of Care Committee Pulmonary embolism guidelineThorax20035847048312775856
   PubMedGoogle Scholar
• The Scottish Intercollegiate Guidelines Network (SIGN). Available from http://www.sign.ac.uk/ Accessed March 10, 2009.
   Google Scholar
• BaglinTBarrowcliffeTWCohenAGreavesMGuidelines on the use and monitoring of heparinBr J Haematol2006133193416512825
   PubMed Web of Science ®Google Scholar
• Royal College of Obstetrics and Gynaecology. Guideline 28. Thromboembolic disease in pregnancy and the puerperium: Acute managementLondon UKRoyal College of Obstetrics and Gynaecology2001Available from http://www.rcog.org.uk/ Accessed March 10, 2009.
   Google Scholar
• Report of the Independent Expert Working Group on the prevention of venous thromboembolism in hospitalized patients. Department of Health. Available from http://www.doh.gov.uk/ Accessed March 10, 2009.
   Google Scholar
• National Institute for Health and Clinical ExcellenceGuideline 46. VTE: Reducing the risk of VTE (DVT and PE) in in-patients undergoing surgery. 2008. Available from http://www.nice.org.uk/ Accessed March 10, 2009.
   Google Scholar
• TanKTLipGYFondaparinuxCurr Pharm Des20051141541915725062
   PubMed Web of Science ®Google Scholar
• GrossPLWeitzJINew anticoagulants for treatment of venous thromboembolismArterioscler Thromb Vasc Biol20082838038618296593
   PubMed Web of Science ®Google Scholar
• CrowtherMAWarkentinTEBleeding risk and the management of bleeding complications in patients undergoing anticoagulant therapy: focus on new anticoagulant agentsBlood20081114871487918309033
   PubMed Web of Science ®Google Scholar
• HirshJO’DonnellMEikelboomJWBeyond unfractionated heparin and warfarinCirculation200711655256017664384
   PubMed Web of Science ®Google Scholar
• KhooCWTayKHShantsilaELipGYHNovel oral anticoagulantsInt J Clin Pract20096363064119222611
   PubMed Web of Science ®Google Scholar
• ShantsilaELipGYApixaban, an oral, direct inhibitor of activated Factor XaCurr Opin Investig Drugs2008910201033
   PubMedGoogle Scholar
• KakarPWatsonTLipGYRivaroxabanDrugs Today20074312913617380210
   PubMed Web of Science ®Google Scholar
• StangierJRathgenKStahleHGansserDRothWThe pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjectsBr J Clin Pharmacol20076429230317506785
   PubMed Web of Science ®Google Scholar
• ErikssonBIDahlOEAhnfeltLDose escalating safety study of a new oral direct thrombin inhibitor, dabigatran etexilate, in patients undergoing total hip replacement: BISTRO IJ Thromb Haemost200421573158015333033
   PubMed Web of Science ®Google Scholar
• ErikssonBIDahlOEBullerHRBISTRO II Study GroupA new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: The BISTRO II randomized trialJ Thromb Haemost2005310311115634273
   PubMed Web of Science ®Google Scholar
• EzekowitzMDReillyPANehmizGDabigatran with or without concomitant aspirin compared with warfarin alone in patients with nonvalvular atrial fibrillation (PETRO Study)Am J Cardiol20071001419142617950801
   PubMed Web of Science ®Google Scholar
• ErikssonBIDahlOERosencherNRE-NOVATE Study GroupDabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomized, double-blind, non-inferiority trialLancet200737094995617869635
   PubMed Web of Science ®Google Scholar
• ErikssonBIDahlOERosencherNRE-MODEL Study GroupOral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trialJ Thromb Haemost200752178218517764540
   PubMed Web of Science ®Google Scholar
• GinsbergJSDavidsonBLRE-MOBILIZE Writing Committee. Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery200924119
   Google Scholar
• National Institute for Health and Clinical ExcellenceFinal appraisal determination. Dabigatran etexilate for the prevention of VTE after hip or knee replacement surgery in adults2008Available from http://www.nice.org.uk/ Accessed March 10, 2009.
   Google Scholar
• EikleboomJEWeitzJIDabigatran etexilate for prevention of venous thromboembolismThromb Haemost2009101doi:10.1160/TH08-10-0708.
   Web of Science ®Google Scholar
• KubitzaDBeckaMVoithBZuehlsdorfMWensingGSafety, pharmacodynamics, and pharmacokinetics of single doses of BAY59-7939, an oral, direct factor Xa inhibitorClin Pharmacol Ther20057841242116198660
   PubMed Web of Science ®Google Scholar
• PerzbornEStrassburgerJWilmenAIn vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939 – an oral, direct factor Xa inhibitorJ Thromb Haemost2005351452115748242
   PubMed Web of Science ®Google Scholar
• ErikssonBIBorrisLCFriedmanRJRECORD1 Study GroupRivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplastyN Engl J Med20083582765277518579811
   PubMed Web of Science ®Google Scholar
• KakkarAKBrennerBDahlOERECORD2 InvestigatorsExtended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled studyLancet20083719632313918582928
   PubMedGoogle Scholar
• LassenMRAgenoWBorrisLCRECORD3 InvestigatorsRivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplastyN Engl J Med20083582776278618579812
   PubMed Web of Science ®Google Scholar
• AgnelliGGallusAGoldhaberSZthe ODIXa-DVT Study InvestigatorsTreatment of proximal deep-vein thrombosis with the oral direct factor Xa inhibitor rivaroxaban (BAY 59-7939): the ODIXa-DVT studyCirculation200711618018717576867
   PubMed Web of Science ®Google Scholar
• BullerHRLensingAWAPrinsMHthe Einstein-DVT Dose-Ranging Study InvestigatorsA dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: the Einstein-DVT Dose-Ranging StudyBlood20081122242224718621928
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Clinical ExcellenceFinal appraisal determination. Rivaroxaban for the prevention of VTE after hip or knee replacement in adultsMarch 5, 2009. Available from http://www.nice.org.uk/guidance/index.jsp?action=download&o=43417 Accessed March 10, 2009.
   Google Scholar
• WongPCCrainEJXinBApixaban, an oral, direct and highly selective factor Xa inhibitor: in vitro, antithrombotic and antihemostatic studiesJ Thromb Haemost2008682082918315548
   PubMed Web of Science ®Google Scholar
• LassenMRDavidsonBLGallusAPineoGAnsellJDeitchmanDThe efficacy and safety of apixaban, an oral, direct factor Xa inhibitor, as thromboprophylaxis in patients following total knee replacementJ Thromb Haemost200752368237517868430
   PubMed Web of Science ®Google Scholar
• BullerHDeitchmanDPrinsMSegersABotticelli InvestigatorsEfficacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep vein thrombosis. The Botticelli DVT dose-ranging studyJ Thromb Haemost200861313131818541000
   PubMed Web of Science ®Google Scholar
• TurpieAGBauerKADavidsonBLEXPERT Study GroupA randomized evaluation of betrixaban, an oral factor Xa inhibitor, for prevention of thromboembolic events after total knee replacement (EXPERT)Thromb Haemost2009101687619132191
   PubMed Web of Science ®Google Scholar
• National Patients Safety AgencyPatient Safety Alert 18. Actions that can make anticoagulant therapy safer2008. Available from: http://www.npsa.nhs.uk/health/alerts Accessed March 15, 2009.
   Google Scholar
• Department of Health. The VTE Implementation Working Group. September 18, 2008. Available from: http://www.dh.gov.uk/en/Publichealth/Healthprotection/Bloodsafety/DH_082132
   Google Scholar
• WeitzJIHirshJSamamaMMAmerican College of Chest PhysiciansNew antithrombotic drugs: American College of Chest Physicians Evidence-Based. Clinical Practice Guidelines (8th Edition)Chest20081336 Suppl234S256S Erratum in Chest. 2008;134:473.18574267
   PubMed Web of Science ®Google Scholar